Neurosurgery scope and subspecialization
Halpern explains what neurosurgeons treat across brain, spine, and peripheral nerves. He describes modern subspecialization and his focus in stereotactic functional neurosurgery.
In this Huberman Lab Essentials episode, my guest is Dr. Casey Halpern, MD, a professor of neurosurgery at the Perelman School of Medicine at the University of Pennsylvania. We discuss how deep brain stimulation and other neuromodulation approaches are being used to treat Parkinson's disease, obsessive-compulsive disorder (OCD), binge eating disorder and depression-related symptoms. We also explore the brain circuits that drive compulsions, cravings and impulsivity, as well as emerging non-invasive tools for predicting and treating harmful behaviors. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Function: https://functionhealth.com/huberman Rorra: https://rorra.com.huberman
Halpern explains what neurosurgeons treat across brain, spine, and peripheral nerves. He describes modern subspecialization and his focus in stereotactic functional neurosurgery.
DBS involves implanting thin insulated leads into specific brain targets. Therapy comes from delivering adjustable electrical stimulation through tiny contacts to modulate local circuits.
Stimulating nearby regions can briefly trigger laughter, panic, or other emotional states. Those transient effects can reveal therapeutic targets for mood and compulsive symptoms.
Some Parkinson’s patients report reduced gambling, improved mood, or less compulsivity after DBS for tremor. This suggests motor targets can intersect with limbic and reward circuitry.
He frames obsessionality and compulsivity as traits that can be adaptive when controlled. OCD is when obsessions and compulsions become intrusive, uncontrollable, and impairing.
SSRIs and certain tricyclics are common medication approaches targeting serotonin-related systems. Exposure and response prevention is highlighted as highly effective but not sufficient for all patients.
A subset of patients remains severely symptomatic despite meds and therapy. For them, DBS or lesion procedures like capsulotomy may be considered with careful risk-benefit counseling.
DBS is adjustable and reversible in effect, while ablation destroys a small brain region. He notes ablations can help with few obvious side effects but remain irreversible surgery.
He cites responder rates around 50% for current surgical approaches, with many responders still symptomatic. This motivates more symptom-specific targeting and personalized circuit approaches.
He describes hyperfunctioning prefrontal and orbitofrontal cortex with projections into basal ganglia circuits. The ventral striatum becomes a key node for compulsive behavior gating.
The ventral striatum, including nucleus accumbens, is discussed as central to reward seeking and compulsion. Disruption can shift behavior toward pursuing reward despite punishment.
He links OCD, addiction, and some eating disorders through persistent urges that override judgment and safety. This common denominator guides target selection and translational research.
Nucleus accumbens is positioned as an integrative reward circuit hub. Pathology arises when strong repeated rewards or stressors hijack normal control and amplify maladaptive urges.
In Parkinson’s, surgeons can detect tremor-related neural patterns to guide placement. Halpern aims to find analogous “craving” or “obsession” signals to improve psychiatric targeting.
He prefers the term craving because patients recognize and report it reliably. It can be more accessible than labels like loss of control or binge behavior for some individuals.
He describes a single-case effort to identify neural activity linked to obsessions intraoperatively. The goal is to optimize electrode placement by anchoring to disease-relevant physiology.
Halpern argues non-invasive approaches should be embraced but made more precise. He notes mechanisms are often unclear, similar to ongoing uncertainty about DBS mechanisms.
He notes TMS is FDA-approved for depression, OCD, and nicotine addiction. TMS may help define circuits and identify candidates who could benefit from invasive trials if effects are temporary.
MRI-guided focused ultrasound is described as an FDA-approved non-invasive ablation for tremor. Research is exploring modulation without lesioning and opening the blood-brain barrier for targeted delivery.
He emphasizes the main barrier is not the tool but target uncertainty. Without knowing the right circuit node, psychiatric ultrasound ablation may only replicate older targets and outcomes.
He describes modern stereoencephalography in epilepsy as safe and informative for locating seizure networks. Similar invasive recordings could map psychiatric circuits and improve targeting strategies.
He outlines a pathway where invasive recordings define reliable targets first. Those pooled data could later support non-invasive targets for ultrasound or other modalities.
He suggests preclinical models can capture aspects of binge and obesity better than some psychiatric syndromes. This supports earlier target development for DBS in those conditions compared to others.
Both discuss whether better interoception and state awareness can prevent episodes. Halpern notes the most severe patients can be highly aware yet still lose control, implying a deeper circuit failure.
He describes implanted devices that record population activity to detect states linked to cravings. The aim is to trigger stimulation at home when patterns indicate elevated risk of binge behavior.
A validated mood provocation protocol is used to induce patient-specific emotional states tied to binge episodes. Brain signals are synchronized with video and eye tracking to capture pre-bite dynamics.
He praises cognitive behavioral approaches while noting relapse can occur when therapy stops. Some patients need sustained intervention to maintain behavior change.
They discuss machine learning using voice, physiology, sleep, and breathing to predict depressive or impulsive episodes before conscious awareness. Halpern argues invasive understanding will sharpen what to look for non-invasively.
Halpern differentiates compulsion as persistent urge despite risk from impulsivity as failure to wait or inhibit action. He connects both to public health concerns like suicidality and addiction.
He acknowledges surgery cannot scale to tens of millions affected by obesity, depression, and addiction. He positions neurosurgical research as a way to rigorously define mechanisms and inspire scalable therapies.